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Abstract
Oral mucositis is one of the most common side effects of chemoradiation regimens and manifestation can be dose-limiting
for the therapy, can impair the patient’s nutritional condition and quality of life due to severe pain. The therapeutic options
are limited; often only an alleviation of the symptoms such as pain reduction by using systemic opioids is possible.
Stimulating opioid receptors on peripheral neurons and dermal tissue, potent analgesic effects are induced e.g. in skin
grafted patients. Advantageous effects on the cell migration and, thus, on the wound healing process are described, too. In
this study, we investigated whether opioid receptors are also expressed on oral epithelial cells and if morphine can
modulate their cell migration behavior. The expression of the opioid receptors MOR, DOR and KOR on primary human oral
epithelial cells was verified. Furthermore, a significantly accelerated cell migration was observed following incubation with
morphine. The effect even slightly exceeded the cell migration stimulating effect of TGF-ß: After 14 h of morphine
treatment about 86% of the wound area was closed, whereas TGF-ß application resulted in a closed wound area of 80%.
With respect to morphine stimulated cell migration we demonstrate that DOR plays a key role and we show the
involvement of the MAPK members Erk 1/2 and p38 using Western blot analysis. Further studies in more complex systems
in vitro and in vivo are required. Nevertheless, these findings might open up a new therapeutic option for the treatment of
oral mucositis.
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Introduction
Oral mucositis (OM) is an acute inflammation and ulceration of
the oral mucosa and often occurs as an adverse effect of chemo-
and/or radiotherapy. The prevalence of OM strongly depends on
the malign underlying disease and the required therapy regimen.
About 30% of patients during or after chemotherapeutic treatment
of many solid tumors and almost 100% of the patients undergoing
a hematopoietic stem cell transplantation or radiotherapy of
tumors in the head and neck area are affected [1,2].
The occurrence of OM includes various symptoms beginning
with slight redness up to deep ulcerations of the mucosa which is a
dose-limiting factor for the chemotherapy, can impair the
nutritional condition and liquid intake, affects the quality of life
due to severe pain, and may result in serious clinical complications
such as secondary fungal or viral infections. The patients
experience OM as one of the most serious side effects of tumor
therapy due to the severe pain which often results in a dropout or
suboptimal dosing [3]. As a consequence the mortality of tumor
patients with OM is increased. The clinical course of OM
comprises five stages: Initiation, inflammation, aggravation,
ulceration and finally healing [3]. Currently, complete prevention
is not possible and the disease management is still complicated for
both the patient and health provider as the therapeutic options are
limited. General approaches include effective oral care (antiseptics
etc.), topical mucosal protectants and dietary modifications. For
the treatment of OM following hematopoietic stem cell transplan-
tation palifermin, a recombinant keratinocyte growth factor, is
approved. However, this only reflects 4% of the cases. Thus, the
cornerstones of the therapy remain the use of topical anesthetics
and for more severe cases the systemic use of analgesics, especially
opioids [4]. Systemic application of opioids requires balancing the
pain relief and the undesirable side effects such as nausea,
vomiting, mental clouding, constipation and sedation [5,6].
Therefore, local opioid application would be advantageous to
reduce opioid-associated adverse effects. The rational basis for this
approach is the expression of opioid receptors outside of the
central nervous system on peripheral sensory neurons, tissues and
cells such as keratinocytes and fibroblasts [6,7,8,9,10] and the
induction of potent analgesic effects by activating these peripheral
receptors [11,12,13]. Moreover, following topical application
[14,15,16,17], adverse effects are reduced. Additionally, opioids
also modulate cell proliferation and survival (Chen, Law et al.
2008) and facilitate the wound healing and reepithelialization of
skin wounds [9,18] by stimulating keratinocyte migration [19,20]
as demonstrated repeatedly in vitro and in vivo. Furthermore, a
functional role of opioids in the context of inflammation is well
documented [11,13].
Based on those results we investigated whether topically applied
opioids - particularly morphine - might be a new therapeutic
option for the treatment of OM with respect to pain relief and
improved wound healing. Potent pain relief in patients suffering
from OM was already shown when applying morphine locally as
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mouthwash [21]. In this study, we investigated whether opioid
receptors are expressed on oral epithelial primary cells and cell




Morphine hydrochloride was purchased from Fagron (Barsbu¨t-
tel, Germany), naloxone hydrochloride dihydrate, nor-Binaltor-
phimine dihydrochloride, naltrindole hydrochloride, DAMGO
([D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin acetate salt, DPDPE
([D-Pen2,D-Pen5]-enkephalin hydrate), 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), bovine serum albu-
min (BSA), U-69593 ((+)-(5a,7a,8b)-N-methyl-N-[7-(1-pyrrolidi-
nyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide, U0126 (1,4-Di-
amino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene
monoethanolate) and transforming growth factor-b1 (TGF-ß1)
were obtained from Sigma-Aldrich (Munich, Germany), CTOP
(H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2) was pur-
chased from Bachem (Bubendorf, Switzerland). Test substances
were dissolved in phosphate-buffered saline (PBS, pH 7.4) with
0.4% BSA. U-69593 and U0126 were dissolved in dimethylsulf-
oxide (DMSO). TR146 cell line was obtained from the Imperial
Cancer Research Technology (London, UK). Primary human oral
keratinocytes (HOK) were purchased from Sciencell Research
Laboratories (Carlsbad, CA, USA), the neuroblastoma cell line
SHSY5Y was a gift from Prof. Dr. med. Christoph Stein (Charite´
Campus Benjamin Franklin, Berlin, Germany).
All solvents and diluents were purchased from Carl Roth
(Karlsruhe, Germany).
Cell Culture
TR146 cells, a human buccal tumour cell line, were maintained
in 75 cm2 flasks (TPP Techno Plastic Products, Trasadingen,
Switzerland) with Dulbecco’s Modified Eagle’s Medium/Nutrient
Mixture F-12 (Sigma-Aldrich) supplemented with 10% fetal calf
serum (FCS, Biochrom, Berlin, Germany), L-glutamine (5 mM)
and penicillin/streptomycin (PAA Laboratories, Pasching, Aus-
tria). Cells were grown at 37uC and 5% CO2 and medium was
changed every two or three days. At confluence, cells were split
1:10 or 1:15. Primary human oral keratinocytes (HOK) were
cultured in 75 cm2 flasks pre-coated with 2 mg/cm2 of poly-L-
lysine using oral keratinocyte medium. Medium was changed
every two to three days until a confluence of 70%–80%. SHSY5Y
cells was also cultured in 75 cm2 culture flasks and was grown in
DMEM/HAM’s F12 supplemented with 10% FCS, 1% penicil-
lin/streptomycin, 1% glutamine und 10 mM non-essential amino
acids solution (Biochrom).
Primary human keratinocytes (NHK) were isolated from
juvenile foreskin after circumcision surgeries. Keratinocytes were
grown in keratinocyte growth medium containing epidermal
growth factor, insulin, gentamicin sulfate, amphotericin B,
hydrocortisone and bovine pituitary extract (Lonza, Walkersville,
MD, USA). Keratinocytes of the second or third passage were
used for the experiments [22]. All cell lines were tested regularly
for mycoplasma using VenorHGem (Minerva Biolabs, Berlin,
Germany) mycoplasma detection kit according to manufacture
protocol.
Reverse Transcription-PCR
RNA was isolated from TR146, HOK, SHSY5Y and NHK
using NucleoSpinH RNA II kit (Macherey-Nagel, Du¨ren, Ger-
many) as described by the manufacturer. Total RNA amount and
purity were determined using UV spectroscopy (wavelength
setting: 260 nm and 280 nm) and gel electrophoresis. Prior to
cDNA synthesis, the RNA samples were treated with DNase
amplification grade I (Sigma-Aldrich, Steinheim, Germany),
subsequently cDNA was generated using the FermentasAidTM
First strand cDNA synthesis kit (Fermentas, St Leon-Rot,
Germany). For relative quantification of opioid receptor expres-
sion RT-PCR was performed using a LightCycler 480 and the
SYBR Green I Masterplus kit (Roche, Penzberg, Germany)
according to manufacturer’s instruction. Primer sequences are
shown in table 1. Primers (TIB Molbiol, Berlin, Germany) were
dissolved in molecular grade water to a final concentration of
10 mM. The mRNA expression levels of each of the targeted genes
are presented as a ratio to the housekeeping gene YWHAZ. PCR
product sizes were checked using a 2% agarose gel.
Immunocytochemistry
To investigate opioid receptor expression on the protein level,
immunocytochemistry was performed. TR146, HOK, SHSY5Y
cells were fixed in 4% paraformaldehyde solution (in PBS, pH 7.4)
for 20 min. Slides were washed in ice cold PBS and blocked with
1% BSA (Aurion, Wageningen, Netherlands) for 1 h at room
temperature. Each slide was incubated with one of the primary
antibodies anti-MOR (mu Opioid Receptor), anti-KOR (kappa
Opioid Receptor) and anti-DOR (delta Opioid Receptor) (rabbit,
Abcam, Cambridge, UK) at 4uC overnight, subsequently washed
three times with PBST, followed by a one hour incubation with
the fluorescein isothiocyanate (FITC) conjugated secondary anti-
rabbit antibody (Abcam, Cambridge, UK). Afterwards, the slides
were washed, covered with mounting medium DAPI (Dianova,
Hamburg, Germany), and visualized using a Keyence digital
microscope BZ-8000 (Keyence, Neu-Isenburg, Germany).
In Vitro Wound Healing Assay
To investigate the effect of opioids on cell migration and wound
closure of oral epithelial cells, the scratch assay was performed.
Cells were seeded in six-well plates (TPP, Trasadingen, Switzer-
land) in a density of 26105 cells/well. After 48 h, a scratch was
made through each well using a sterile pipette tip. Morphine (in
PBS plus 0.4% BSA) was added in a concentration range of 1 nM
to 10 mM. TGF-ß (1 ng/ml) served as positive control (for review,
see [23]). Scratches were investigated under the microscope
(magnification 1006) immediately after wounding and after
cultivation in an incubator (37uC, 5% CO2) for 14 hours. Pictures
were taken exactly at the same position before and after the
Table 1. Primer sequences and expected product size (bp)
for the target and reference genes. Primer efficiency was
.1.89, respectively.
Opioid Receptor (OR) Primer sequences (59R39) bp
DOR forward ACCAGCACGCTGCCTTTCC 155
DOR reverse ACAGCGATGTAGCGGTCAACAC
MOR forward TCCAGACTGTTTCTTGGCACTTC 130
MOR reverse GAAGAGGTTGGGATACAGAACTCTC
KOR forward CGTCTGCTACACCCTGATGATC 64
KOR reverse CTCTCGGGAGCCAGAAAGG
YWHAZ forward AGACGGAAGGTGCTGAGAAA 127
YWHAZ reverse GAAGCATTGGGGATCAAGAA
doi:10.1371/journal.pone.0042616.t001
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incubation. To check for opioid-receptor mediated effects, a pre-
incubation of the cells with the opioid receptor antagonist
naloxone (10 mM for 1 h) was performed. In order to identify
the opioid receptor being responsible for the cell migration
enhancement, cells were also stimulated with DAMGO, DPDPE
and U-69593 - MOR, DOR and KOR specific agonists -
respectively. Additionally, prior to morphine stimulation we also
pre-incubated the cells with selective MOR (CTOP), KOR (nor-
Binaltorphimine dihydrochloride) and DOR (naltrindole hydro-
chloride) antagonists. For data evaluation, wound closure rate was
calculated using the T scratch analysis software [24] which is
based on image analysis technique and enables an automated
calculation of the repair process.
Knock Down of DOR, MOR and KOR using siRNA
To further elucidate the role of the opioid receptors on epithelial
cell migration, TR146 cells were transfected with selective siRNAs
for MOR (siRNA ID # s9871), DOR (siRNA ID # s9862), and
KOR (siRNA ID # s9867) obtained from Ambion (Life
Technologies, Darmstadt, Germany). For control, scrambled
siRNA (Invitrogen, Carlsbad, CA, USA) was used. Prior to
transfection, the siRNA was complexed with HiPerFect transfec-
tion Reagent (Qiagen, Hilden, Germany). 26105 cells/well were
seeded in 6-well plates. The siRNA complex was added to a final
concentration of 10 nM. Cells were incubated at 37uC, 5% CO2
for 48 h. Afterwards, RNA was isolated and RT-PCR was
performed to assess the knock down efficiency.
After confirming sufficient knock down, the in vitro wound
healing assay was performed (as described above).
Cell Proliferation
The cell proliferation rate was assessed using CalbiochemHBrdU
cell proliferation kit (Merck, Darmstadt, Germany). The prolifer-
ation kit detects 5-bromo-29-deoxyuridine (BrdU) incorporation
into cellular DNA during cell proliferation. Cells were seeded in 96-
well plates. After cell attachment, they were stimulated with
morphine in a concentration range from 1 nM to 100 mM. After
4 hours of stimulation 20 ml BrdU was added and the colored
reaction product was quantified using a spectrophotometer
(FLUOstar Optima, BMG LABTECH, Ortenberg, Germany),
results were normalized to the untreated control.
Cell Viability
For cell viability testing, the activity of the cellular mitochon-
drial dehydrogenase was determined by measuring MTT reduc-
tion and conversion into a blue formazan salt as described
previously [25]. 16104 TR146 cells/well were seeded into 96-well.
After 24 hours, the cells were stimulated with different concen-
trations of morphine for 14 h and 24 h at 37uC, respectively.
Subsequently, 10 ml/well of MTT solution (5 mg/ml) were added.
After 4 hours, the supernatants were removed, 50 ml of dimethyl-
sulfoxide (DMSO) was added to dissolve the formazan salt and its
optical density (OD) was measured using the FLUOstar Optima
setting the absorbance to 540 nm [22]. Sodium dodecyl sulfate
(0.01%) served as positive control. Each concentration was tested
in triplicate and the experiments were repeated three times. A cell
viability ,70% predicts cytotoxic effects. The experiment was
performed with the primary HOK, too.
Determination of the Involvement of MAPK in Morphine
Stimulated Cell Migration
256104 TR146 cells were seeded in six-well plates till
confluence. To determine the involvement of Erk (Extracellular
signal-regulated kinase) phosphorylation on morphine stimulated
cell migration, cells were pre-incubated with 10 mM U0126 for
30 min. U0126 is a selective inhibitor of the protein kinases
MEK1 and MEK2 which leads to the inhibition of the
phosphorylation of Erk 1 and 2 [26]. Afterwards, cell migration
was investigated as previously described.
Additionally, Western blot analysis was performed. After
stimulation with morphine, cells were rinsed twice with ice-cold
PBS, scraped and lysed with radioimmunoprecipitation assay
buffer containing 150 mM NaCl, 50 mM Tris, 1% Triton X-100,
0.5% sodium deoxycholate,and 0.1% SDS, supplemented with
protease inhibitors (2 g/ml aprotinin, 10 g/ml leupeptin, 1 g/ml
pepstatin A, 1 mM phenylmethylsulfonylfluoride, 5 mM EDTA,
1 mM sodium orthovanadate, 10 mM sodium fluoride). Lysates
were centrifuged for 30 min. Total protein concentrations were
determined with the PierceH BCA Protein Assay Kit (Thermo
scientific, Rockford, USA). Samples containing 50 mg protein was
boiled in SDS sample buffer (100 mM Tris/HCl (pH 6.8), 4%
SDS, 0.2% bromophenol blue, 20% glycerol, 200 mM dithio-
threitol) for 5 minutes and separated by 10% SDS-PAGE.
Subsequently gels were semi-dry blotted on polyvinylidene
difluoride membranes. After blocking with 5% non-fat dry milk,
membranes were probed for the MAPK (Mitogen-activated
protein kinase) expression using phospho-p44/42 MAPK (Erk
1/2), p44/42 MAPK (Erk 1/2), phospho-p38 MAPK, p38
MAPK, phospho-JNK 1/2 or JNK 1/2 (Jun NH2-Terminal
Kinase), respectively (Cell Signaling Technology, Danvers, MA,
USA), at a concentration of 1:1.000 overnight at 4uC. Afterwards,
the membranes were incubated with horseradish peroxidase-
conjugated secondary antibody (1 : 1.000) for 1 hour at room
temperature and the blots were developed by chemiluminescence
with 20X LumiGLOH and 20X Peroxide (CellSignaling Technol-
ogy, Danvers, MA, USA). Bands were visualized with Chemi-
DocTM XRS+ (Bio-RAD, USA), quantitative measurements were
recorded using Image Lab (Beta 2) (Bio-RAD, USA). The
expression of the phosphorylated form of each MAPK member
was normalized against the expression level of its total amount. ß-
Actin served as loading control.
Statistics
All values are expressed as mean6 SEM obtained from three to
five independent experiments. For the statistical analysis the
unpaired t-test was performed. Differences are considered to be
significant at *p#0.05, **p#0.01 and ***p#0.001.
Results
Expression of the Opioid Receptors MOR, DOR and KOR
in Oral Epithelial Cells
To clarify whether OR (Opioid Receptors) are present in the
oral epithelium and to compare their expression to the central
nervous system and to normal human keratinocytes, we deter-
mined the mRNA expression of the three OR types (MOR),
(KOR) and (DOR) in the oral epithelial cell line TR146 and
human oral keratinocytes (HOK). SHSY5Y and NHK served as
control. In TR146 and HOK, all three opioid receptors are
expressed on mRNA (Fig. 1) and protein level (Fig. 2), respectively.
As expected, mRNA expression is significantly lower compared to
SHSY5Y (Fig. 1). We found higher expression of DOR compared
to MOR in TR146 and HOK. Surprisingly, only traces of MOR
were detected in HOK (Fig. 1). The PCR products were checked
by gel electrophoresis, bands were detected at 150 bp (MOR),
155 bp (DOR) and 64 bp (KOR) (data not shown).
Effect of Morphine on Oral Epithelial Cells
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Figure 1. Relative mRNA expression of opioid receptors of MOR, DOR, KOR in SHSY5Y, TR146, HOK and NHK. Expression levels of KOR,
MOR and DOR mRNA were normalized to the housekeeping gene YWHAZ, n= 5.
doi:10.1371/journal.pone.0042616.g001
Figure 2. Immunostaining of MOR, DOR and KOR in SHSY5Y, TR146 and HOK. Scale bar: 50 mm, magnification 2006. Nuclei were
stained with DAPI.
doi:10.1371/journal.pone.0042616.g002
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Based on these results we decided to continue the majority of
experiments with TR146 due to much easier handling and faster
cell proliferation compared to HOK. Nevertheless, all experiments
were repeated with HOK to ensure the transferability and
consistency of the results.
Wound Healing Assay
Next we investigated the effects of morphine on the cell
migration of oral epithelial cells and its ability to accelerate the
closure of a ‘wound’ that has been created by scratching through a
cell monolayer (scratch assay). First, we determined the impact of
morphine on the cell migration (Fig. 3 A, 3 B). Clearly dose-
dependent effects were observed showing particular fast migration
for a morphine concentration of 100 nM (86% closed wound area
versus 28% of the control). Surprisingly, this effect decreased
slightly when morphine concentrations were raised up to 1 mM
(75% closed wound area) and 10 mM (73% closed wound area).
Thus, further experiments were conducted with a morphine
concentration of 100 nM. An almost complete ‘wound closure’
was observed after 14 hours. The effect was even more
pronounced than with the positive control TGF-ß (80% closed
wound area; Fig. 3 A).
To investigate whether this migration enhancing effect by
morphine is opioid-receptor mediated, cells were pre-incubated
with the non-selective opioid receptor antagonist naloxone
(10 mM) for 1 h at 37uC. Subsequently, morphine was added.
The closed wound area significantly decreased, respectively,
whereas no significant changes were observed for TGF-ß or the
negative control (Fig. 3). Consistent results were seen with the
primary oral keratinocytes, too (data not shown).
To elucidate which receptor is responsible for the stimulation of
cell migration the cells were pre-incubated with the selective DOR
antagonist naltrindole (10 mM), selective MOR antagonist CTOP
(10 mM) and the selective KOR antagonist nor-Binaltorphimine
(10 mM). After pre-treatment following morphine application with
MOR and KOR selective antagonist about 79% of the wound
area was closed. In contrast, after pre-incubation with the selective
DOR antagonist naltrindole only about 22% of the scratch area
was closed (Fig. 4). No inhibiting effect was seen on the TGF-ß
mediated cell migration (Fig. 4 B).
The results were confirmed by using the selective opioid
receptor agonists: DAMGO for MOR, DPDPE for DOR and U-
69593 for KOR. The selective DOR agonist DPDPE (100 nm,
81% closed wound area) enhanced the migration to a similar
degree like morphine (84%) and TGF-ß (82%). In contrast, cell
stimulation with DAMGO or U-69593 did not enhance the
wound closure (Fig. 5). These results were confirmed with HOK,
too.
Figure 3. A Effect of morphine on closing an artificial ‘wound’ in TR146 cells. Confluent cell cultures were stimulated with 0.01, 0.1,
1, and 10 mM morphine and incubated for 14 h (gray columns). Morphine accelerated the closure of the scratch significantly compared to
untreated cells (0) and TGF-ß. Pre-incubation with naloxone (10 mM) for 1 h resulted in the significant reduction of the closed wound area % (black
column). *p#0.05, **p#0.01. B Representative pictures of the Scratch Assay.TR146 were stimulated with morphine (100 nM) or TGF-ß (1 ng/ml) for
14 h at 37uC. A) depicts the scratch right after wounding, B) after 14 h of incubation, n = 6.
doi:10.1371/journal.pone.0042616.g003
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The key role of DOR was further substantiated by siRNA
experiments. After 48 h of incubation, knock down efficiency for
MOR, DOR and KOR was 74.566.8%, 76.3612% and
7467.4%, respectively. The scratch assay showed a significant
reduction in the migration of DOR knock down cells (wound
closure rate: 14%). In contrast, no effects were seen for MOR
(wound closure rate: 80%) and KOR knock down cells (wound
closure rate: 82%) (Fig. 6 A, B).
Cell Viability and Proliferation
BrdU assay was performed in order to clarify whether the cell
migration enhancing effect of morphine may be biased by a
stimulation of cell proliferation. Morphine stimulated oral
epithelial cells (TR146 and HOK) did not show a significant
increase in cell proliferation at any concentration (data not shown).
In contrast, TGF-ß exposure did result in significant increase of
cell proliferation.
To ensure that morphine does not exhibit cytotoxic effects on
oral epithelial cells, MTT test was performed. No cytotoxicity was
found for morphine when applied in a concentration range from
1 nM up to 100 mM (data not shown).
Determination of the Involvement of MAPK in Morphine
Stimulated Cell Migration
To elucidate the role of Erk 1/2 in oral epithelial cell migration
in response to morphine stimulation, we first performed in vitro
wound healing assay in the presence of the selective Erk1/2
inhibitor U0126. After 14 hours cell migration was not stimulated
– the cell migration enhancing effect of morphine and TGF-ß was
completely antagonized. Only 18% and 20% of the wound area
was closed after treatment with morphine (100 nM) and TGF-ß
(1 ng/ml) in the presences of U0126 indicating that Erk 1/2 is a
crucial component of the cell migratory pathway activated by
morphine and TGF-ß (data not shown). Additionally, Western blot
analysis of the phosphorylated (p-) Erk 1/2, total Erk 1/2, p-p38
MAPK, p38 MAPK, p-JNK 1/2 and JNK 1/2 after stimulation
with morphine and TGF-ß was performed. The results showed a
time dependent increase of Erk 1/2 and p38 phosphorylation in
response to morphine, whereas this effect was blocked when the
Figure 4. A Scratch Assay. A) depicts the scratch right after wounding, B) after 14 h of incubation. Migration enhancing effect of morphine was
inhibited by naloxone and naltrindole indicating a DOR mediated effect (n = 5). B Effect of selective opioid receptors antagonist on wound closure
ofTR146; Closed wound area % after 14 hours of treatment, pre-incubation with NL; naloxone 10 mM, m ); MOR antagonist, D ); DOR antagonist, k
); KOR antagonist for 1 hour prior to cell stimulation with morphine (n = 5). The OR antagonists did not show any effect on TGF-ß stimulated cell
migration. ***p#0.001.
doi:10.1371/journal.pone.0042616.g004
Figure 5. Effect of selective opioid receptor agonists on the
‘wound closure’ in TR146 cells. Closed wound area % after 14 hours
of exposure with selective opioid receptor agonist for MOR (DAMGO),
KOR (U-69593) and DOR (DPDPE) (100 nM) in comparison to morphine
(100 nM). TGF-ß (1 ng/ml) served as a positive control, (n = 3).***p#0.001.
doi:10.1371/journal.pone.0042616.g005
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cells where pre-incubated with U0126 (Fig. 7 A). The phosphor-
ylated form of JNK1/2 did not show a significant increase with
morphine but a pronounced effect with TGF-ß. Quantitative
analysis showed a two fold increase of both p-Erk and p-p38 after
10 minutes stimulation with morphine (Fig. 7 B).
Discussion
Peripheral antinociceptive effects of opioids have been first
described about thirty years ago [27]. In the 1990s, evidence
emerged that such effects are mediated by opioid receptors
localized on peripheral sensory neurons and tissues [10]. Later on
opioid receptors have also been found on immune cells such as
lymphocytes, granulocytes etc. and on dermal structures such as
keratinocytes and fibroblasts (for review see: [9]). The expression
of opioid receptors on dermal structures is important for the cross-
talk between nerves and skin in terms of analgesia, cell
differentiation and migration. Furthermore, various studies
describe the stimulating effects of endogenous and exogenous
opioid receptor agonists on keratinocyte migration, and thus, on
the formation of granulation tissue and reepithelialization of
wounds [19,20,28]. In our study we investigated whether opioid
receptors are also present on oral epithelial cells and how opioid
receptor agonists influence cell behavior in terms of cell migration.
These information might open up a new therapeutic rational for
the treatment of oral ulcers occurring for example during oral
mucositis. For this purpose we used the oral epithelial cell line
TR146 which despite being isolated from a squamous cell
carcinoma of the buccal mucosa expresses all natural major
markers of the epithelial basal membrane and of epithelial
differentiation [29]. Additionally, TR146 is also used for the
construction of in vitro oral epithelial models [30]. To ensure the
transferability of results and data, we also repeated the experi-
ments using primary human oral keratinocytes. No differences
between the cell line and the primary cells were observed.
All major opioid receptors mu-, delta-, and kappa are expressed
in TR146 and primary HOK (Fig. 1 A, 1 B, 2). As expected,
expression levels were lower compared to the neuroblastoma cell
line SHSY5Y which served as positive control. Interestingly, we
found higher mRNA levels of the DOR in the oral epithelial cells
in comparison to the NHK [7,8,28,31,32], and the neuroblastoma
cells which expresses MOR and DOR abundantly but KOR in
traces only [33,34]. Pain reduction in patients suffering from oral
mucositis when using a morphine mouthwash [14] already
indicated the involvement of peripheral opioid receptors.
Based on those results we investigated the effect of morphine on
cell migration of oral epithelial cells. We opted for the use of
morphine as model opioid receptor agonist as it was previously
shown, that the cell migration enhancing effect of opioids is a
group effect [20]. Here, we were able to demonstrate a stimulating
effect of morphine on the cell migration of oral epithelial cells
(Fig. 3 A, 3 B) which is a prerequisite for reepithelialization and
wound closure in vivo. Morphine facilitated cell migration was dose
dependent. Interestingly, in comparison to NHK complete ‘wound
closure’ was already observed after 14 h incubation with
morphine. With NHK the same effect was measurable not until
48 hours of opioid stimulation [20]. However, further increase in
morphine concentration (up to 10 mM) seemed to have a reverse
effect on the oral epithelial cell migration, though cell migration
was still enhanced compared to the untreated control. Compara-
ble results were described by Ohshima, et al., which observed
similar effects using the epidermal growth factor EGF [35]. Other
Figure 6. A Scratch Assay. A) depicts the scratch right after wounding, B) after 14 h of incubation. Migration enhancing effect of morphine was
inhibited after knock down of DOR using siRNA. Migration was not affected after MOR and KOR knock down (n= 3). B Effect of siRNA knock down of
opioid receptors on the ‘wound closure’; Closed wound area % after 14 hours of morphine treatment, pre-incubated with MOR siRNA, KOR siRNA and
KOR siRNA (n = 3). **p#0.01.
doi:10.1371/journal.pone.0042616.g006
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studies have demonstrated inhibition of angiogenesis by high doses
of morphine and b-endorphin in a CAM assay [36] The reasons
for this are ambiguous, effects of morphine on cell proliferation or
cytotoxicity were excluded. Possibly it is due to nonspecific activity
of excessive morphine dosages [37]. However, further studies on
this are necessary.
The stimulating effect of morphine on the cell migration
vanished when the oral epithelial cells were pre-incubated with the
non-selective opioid receptor antagonist naloxone clearly indicat-
ing an opioid receptor mediated effect. This has also been
described for other cells especially dermal cells, too [18,20]. To
clarify which opioid receptor particularly is responsible for the
stimulation of cell migration we incubated the oral epithelial cells
with selective opioid receptor antagonists and agonists and we
knocked down the expression of MOR, KOR and DOR using
RNA interference prior to the morphine application. We clearly
identified DOR as the responsible receptor. Our findings are well
in accordance with other studies which demonstrated delayed
wound healing and hypertrophic epidermis in DOR knockout
mice [38]. Thus, the key role of DOR in the wound healing
process is emphasized and it can be concluded that DOR is an
important player in cell differentiation and migration during
wound healing.
Obviously, morphine and TGF-ß stimulate the migration of
epithelial cell via similar pathways. In general, TGF-ß initiates
signaling by assembling receptor complexes that activate Smad
transcription factors leading to the regulation of a wide array of
cellular processes such as cell growth and migration [39,40]. TGF-
ß also activates non-Smad pathways including Erk 1/2 MAPK
[41,42], JNK and p38 MAPK [43,44]. Our results are well in
accordance with these findings showing that TGF-ß increases the
phosphorylation of Erk 1/2, p38 and JNK 1/2 (Fig. 7 A). For
morphine, we found a time dependent activation of Erk 1/2 and
p38 MAPK, but not for JNK. Erk 1/2 is crucial for the regulation
of cell migration and proliferation [45,46,47]. p38 MAPK is
important for the migration of human keratinocytes [48].
Furthermore, our studies indicate a positive cross-talk between
p38 and Erk MAPK in oral epithelial as the phosphorylation of
p38 was blocked after the inhibition of Erk 1/2 phosphorylation
using the selective antagonist U0126 (Fig. 7 A). This has been
described previously [49,50]. Similar to oral epithelial cells,
concurrent activation of Erk and p38 occurs in melanoma and
the positive crosstalk between the two MAPK members stimulates
cell migration and proliferation [51]. Although more studies are
required for a full understanding of the exact signaling mecha-
nisms underlying morphine stimulated cell migration, this study
definitely shows the involvement of the MAPK members Erk 1/2
and p38.
In conclusion, our findings might open up a new therapeutic
rational for the treatment of patients with chemo-/radiotherapy-
induced oral mucositis. The basis for this is the presence of ORs
on the oral epithelium. A local application of opioids can allow for
efficient pain reduction, facilitated wound healing and wound
closure due to the stimulation of cell migration. Definitely, further
studies are needed, especially in more complex in vitro and in vivo
systems. Nevertheless, morphine could be an effective and safe
therapeutic option for oral wounds.
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